{
    "clinical_study": {
        "@rank": "82483", 
        "arm_group": [
            {
                "arm_group_label": "nalbuphine HCl ER 60mg", 
                "arm_group_type": "Experimental", 
                "description": "nalbuphine HCl ER tablets 60 mg BID"
            }, 
            {
                "arm_group_label": "nalbuphine HCl ER 120mg", 
                "arm_group_type": "Experimental", 
                "description": "nalbuphine HCl ER tablets 120 mg BID"
            }, 
            {
                "arm_group_label": "Sugar pill", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo tablets BID"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objectives of the study to evaluate the effects of two doses of nalbuphine HCl\n      ER tablets on the change from baseline in the worst itch Numerical Rating Scale (NRS) in\n      hemodialysis patients with moderate to severe uremic pruritus and to evaluate the safety and\n      tolerability in the study population."
        }, 
        "brief_title": "Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Uremic Pruritus", 
            "Pruritus"
        ], 
        "condition_browse": {
            "mesh_term": "Pruritus"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject has been receiving in-center hemodialysis for \u2265 3 months and are currently on\n             a schedule of 3 times a week.\n\n          -  Subject self-categorized themselves on the Patient Assessed Disease Severity Scale\n             during Screening\n\n          -  Subject meets standard of care hemodialysis efficiency guidelines during the three\n             months prior to completing Screening\n\n          -  Have demonstrated pruritus intensity on the Itch NRS during screening\n\n          -  Male or female who are at least 18 years old at the time of Screening\n\n        Exclusion Criteria:\n\n          -  Subject had a significant alteration in dialysis regimen during the Screening Period\n\n          -  Subject receiving or anticipated to be receiving nocturnal dialysis or home\n             hemodialysis treatment during the study.\n\n          -  Subject has pruritus that is believed to be caused by a condition unrelated to\n             end-stage renal disease\n\n          -  Has had a history of substance abuse within 6 months prior to completing Screening\n\n          -  Subject has a known drug allergy to opioids\n\n          -  Subject is a pregnant or lactating female."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "360", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02143648", 
            "org_study_id": "TR02", 
            "secondary_id": "2013-005625-22"
        }, 
        "intervention": [
            {
                "arm_group_label": "nalbuphine HCl ER 60mg", 
                "description": "nalbuphine HCl ER tablets 60 mg BID administered for 6 weeks", 
                "intervention_name": "nalbuphine HCl ER tablets 60 mg BID", 
                "intervention_type": "Drug", 
                "other_name": "nalbuphine ER"
            }, 
            {
                "arm_group_label": "nalbuphine HCl ER 120mg", 
                "description": "nalbuphine HCl ER tablets 120mg BID administered for 6 weeks", 
                "intervention_name": "nalbuphine HCl ER tablets 120mg BID", 
                "intervention_type": "Drug", 
                "other_name": "nalbuphine ER"
            }, 
            {
                "arm_group_label": "Sugar pill", 
                "description": "Placebo tablets BID administered for 8 weeks", 
                "intervention_name": "Placebo tablets BID", 
                "intervention_type": "Drug", 
                "other_name": "sugar pill"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Nalbuphine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "uremic", 
            "pruritus", 
            "itch", 
            "chronic itch", 
            "nalbuphine"
        ], 
        "lastchanged_date": "May 20, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Springfield", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "01107"
                }, 
                "name": "Bay State Health"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Double-Blind, Placebo-Controlled, Parallel, 3-Arm Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus", 
        "other_outcome": [
            {
                "measure": "Change from Baseline to the Evaluation Period in sleep on the 12 question Medical Outcomes Study Sleep Survey's Sleep Problems Index II, SLP-9 (Itch MOS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 7, Week 8"
            }, 
            {
                "measure": "Change from Baseline to the Evaluation Period in depression and anxiety on the 14 question Hospital Anxiety and Depression Scale (HADS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 7, Week 8"
            }, 
            {
                "measure": "Change from Baseline to the Evaluation Period in the patient's assessment of their pruritus on the Patient Assessed Disease Severity Scale (PADS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 7, Week 8"
            }
        ], 
        "overall_contact": {
            "email": "roberta.duncan@trevitherapeutics.com", 
            "last_name": "Roberta Duncan", 
            "phone": "203-304-2499"
        }, 
        "overall_contact_backup": {
            "last_name": "Thomas Sciascia, MD", 
            "phone": "2033042499"
        }, 
        "overall_official": {
            "affiliation": "Trevi Therapeutics", 
            "last_name": "Thomas Sciascia, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from Baseline to the Evaluation Period (weeks 7 and 8) in itch on the 0-10 Itch Numerical Rating Scale", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Week 7, Week 8"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02143648"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Change from Baseline scores to the Evaluation Period (weeks 7 and 8) in the total Skindex-10 score", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Week 7, Week 8"
        }, 
        "source": "Trevi Therapeutics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Trevi Therapeutics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}